 Connection
Stephanie Lakritz to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Stephanie Lakritz has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.570 |
|
|
|
-
Lakritz S, Nicklawsky A, Alami V, Kohli M, Moskaluk C, Riedlinger G, Salhia B, Singer EA, Naqash AR, Nepple K, Edge S, Myint Z, Kolesar J, Adra N, Flaig T, Graham LS. Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations. Clin Genitourin Cancer. 2025 Feb; 23(1):102293.
Score: 0.434
-
Forsberg PA, Rossi AC, Boyer A, Pearse RN, Pekle KA, Jayabalan D, Lakritz S, Flicker K, Ribadeneyra D, Liotta B, Ely S, Boussi L, Allan JN, Coleman M, Niesvizky R, Mark TM. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. Am J Hematol. 2021 12 01; 96(12):1554-1562.
Score: 0.087
-
Roy S, Lakritz S, Schreiber AR, Kuna EM, Bradley CJ, Kondapalli L, Diamond JR. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study. Eur J Cancer. 2024 01; 196:113426.
Score: 0.025
-
Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JR. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023 05; 185:69-82.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|